Researchers have developed a non-invasive way of predicting how much of a cancer-killing drug is absorbed by a tumour. The preliminary study, which will be reported at the 24th EORTC-NCI-AACR Symposium on Molecular Targets ...
Nov 7, 2012
0
0
Adding an aromatase inhibitor to presurgery treatment with docetaxel, carboplatin, trastuzumab (Herceptin), and pertuzumab (Perjeta) did not significantly increase or decrease the percentage of patients with hormone receptor ...
Dec 9, 2016
0
0
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) ...
Sep 6, 2012
0
0
(HealthDay)—For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.
Sep 7, 2013
0
0
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumors Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found ...
Feb 2, 2024
0
0
A 10-year population-based study shows that increased availability of better systemic chemo- and targeted-therapies for patients with advanced non-small cell lung cancer (NSCLC) coincides with increased usage of these therapies. ...
Jul 21, 2014
0
0
(HealthDay)—The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food and Drug Administration ...
Dec 10, 2012
0
1
Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), with the participation of collaborators from the Baylor College of Medicine (Houston) and the University Institute of Oncology of Asturias (IUOPA), publish ...
Jun 18, 2019
0
0
Among patients previously treated for a type of advanced lung cancer, use of a combination treatment did not improve progression-free or overall survival, according to a study published by JAMA.
May 9, 2017
0
0
More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main ...
Nov 29, 2012
0
0
